Would you offer adjuvant HER 2 directed therapy for ER+/PR+/HER2+ pT1-T2 N0 papillary carcinoma of the breast?  

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.



Answer from: Medical Oncologist at Academic Institution